Cargando…

Predictors of long-term cognitive outcome in Alzheimer's disease

INTRODUCTION: The objective of this study was to describe the longitudinal cognitive outcome in Alzheimer's disease (AD) and analyze factors that affect the outcome, including the impact of different cholinesterase inhibitors (ChEI). METHODS: In an open, three-year, nonrandomized, prospective,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wattmo, Carina, Wallin, Åsa K, Londos, Elisabet, Minthon, Lennart
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3226278/ https://www.ncbi.nlm.nih.gov/pubmed/21774798 http://dx.doi.org/10.1186/alzrt85

Ejemplares similares

Galantamine treatment in Alzheimer’s disease: response and long-term outcome in a routine clinical setting
por: Wallin, Åsa K, et al.
Publicado: (2011)

Solitary living in Alzheimer’s disease over 3 years: association between cognitive and functional impairment and community-based services
por: Wattmo, Carina, et al.
Publicado: (2014)

Short-Term Response to Cholinesterase Inhibitors in Alzheimer’s Disease Delays Time to Nursing Home Placement
por: Wattmo, Carina, et al.
Publicado: (2018)

Response to cholinesterase inhibitors affects lifespan in Alzheimer’s disease
por: Wattmo, Carina, et al.
Publicado: (2014)

A Quick Test of cognitive speed is sensitive in detecting early treatment response in Alzheimer's disease
por: Palmqvist, Sebastian, et al.
Publicado: (2010)

Cholinesterase inhibitors do not alter the length of stay in nursing homes among patients with Alzheimer’s disease: a prospective, observational study of factors affecting survival time from admission to death
por: Wattmo, Carina, et al.
Publicado: (2016)

Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy
por: Wattmo, Carina, et al.
Publicado: (2016)

A longitudinal study of risk factors for community-based home help services in Alzheimer’s disease: the influence of cholinesterase inhibitor therapy
por: Wattmo, Carina, et al.
Publicado: (2013)

Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer’s disease cohort
por: Wattmo, Carina, et al.
Publicado: (2012)

Progression of mild Alzheimer’s disease: knowledge and prediction models required for future treatment strategies
por: Wattmo, Carina, et al.
Publicado: (2013)

Comparison of Brief Cognitive Tests and CSF Biomarkers in Predicting Alzheimer’s Disease in Mild Cognitive Impairment: Six-Year Follow-Up Study
por: Palmqvist, Sebastian, et al.
Publicado: (2012)

Early-versus Late-Onset Alzheimer Disease: Long-Term Functional Outcomes, Nursing Home Placement, and Risk Factors for Rate of Progression
por: Wattmo, Carina, et al.
Publicado: (2017)

Early- versus late-onset Alzheimer’s disease in clinical practice: cognitive and global outcomes over 3 years
por: Wattmo, Carina, et al.
Publicado: (2017)

Changes in cognitive domains during three years in patients with Alzheimer's disease treated with donepezil
por: Persson, Cecilia M, et al.
Publicado: (2009)

Reliability, validity and clinical correlates of the Quality of Life in Alzheimer’s disease (QoL-AD) scale in medical inpatients
por: Torisson, Gustav, et al.
Publicado: (2016)

Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application
por: Wattmo, Carina, et al.
Publicado: (2013)

Cognitive impairment is undetected in medical inpatients: a study of mortality and recognition amongst healthcare professionals
por: Torisson, Gustav, et al.
Publicado: (2012)

Kynurenic Acid Levels in Cerebrospinal Fluid from Patients with Alzheimer’s Disease or Dementia with Lewy Bodies
por: Wennström, Malin, et al.
Publicado: (2014)

Longitudinal Study of CSF Biomarkers in Patients with Alzheimer's Disease
por: Buchhave, Peder, et al.
Publicado: (2009)

The Impact of Autonomic Dysfunction on Survival in Patients with Dementia with Lewy Bodies and Parkinson's Disease with Dementia
por: Stubendorff, Kajsa, et al.
Publicado: (2012)

Psychotropic and anti-dementia treatment in elderly persons with clinical signs of dementia with Lewy bodies: a cross-sectional study in 40 nursing homes in Sweden
por: Zahirovic, Iris, et al.
Publicado: (2018)

Cerebrospinal fluid levels of IL-6 are decreased and correlate with cognitive status in DLB patients
por: Wennström, Malin, et al.
Publicado: (2015)

Survival among the older adults with clinical signs of Lewy body dementia in 40 Swedish nursing homes: a 6-year follow-up study
por: Zahirovic, Iris, et al.
Publicado: (2019)

Multidisciplinary intervention reducing readmissions in medical inpatients: a prospective, non-randomized study
por: Torisson, Gustav, et al.
Publicado: (2013)

Importance and added value of functional impairment to predict mortality: a cohort study in Swedish medical inpatients
por: Torisson, Gustav, et al.
Publicado: (2017)

Cerebrospinal Fluid Levels of sAPPα and sAPPβ in Lewy Body and Alzheimer's Disease: Clinical and Neurochemical Correlates
por: Mulugeta, Ezra, et al.
Publicado: (2011)

Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson's disease with dementia: a prospective study
por: Stubendorff, Kajsa, et al.
Publicado: (2014)

Medial temporal lobe atrophy is underreported and may have important clinical correlates in medical inpatients
por: Torisson, Gustav, et al.
Publicado: (2015)

A Longitudinal Study of Physical Function in Patients with Early-Onset Dementia
por: Tangen, Gro Gujord, et al.
Publicado: (2012)

Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease
por: Hansson, Oskar, et al.
Publicado: (2014)

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
por: Wattmo, Carina, et al.
Publicado: (2020)

CCL2 Is Associated with a Faster Rate of Cognitive Decline during Early Stages of Alzheimer's Disease
por: Westin, Karin, et al.
Publicado: (2012)

No Diagnostic Value of Plasma Clusterin in Alzheimer's Disease
por: Silajdžić, Edina, et al.
Publicado: (2012)

A Genetic Variant of the Sortilin 1 Gene is Associated with Reduced Risk of Alzheimer’s Disease
por: Andersson, Carl-Henrik, et al.
Publicado: (2016)

A new automated method for analysis of rCBF-SPECT images based on the active-shape algorithm: normal values
por: Hägerström, Douglas, et al.
Publicado: (2012)

Evaluation of a Previously Suggested Plasma Biomarker Panel to Identify Alzheimer's Disease
por: Björkqvist, Maria, et al.
Publicado: (2012)

SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer’s disease
por: Brinkmalm, Ann, et al.
Publicado: (2014)

Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer's disease
por: Stomrud, Erik, et al.
Publicado: (2010)

Cerebral inflammation is an underlying mechanism of early death in Alzheimer’s disease: a 13-year cause-specific multivariate mortality study
por: Nägga, Katarina, et al.
Publicado: (2014)

Tau Pathology and Parietal White Matter Lesions Have Independent but Synergistic Effects on Early Development of Alzheimer's Disease
por: Hertze, Joakim, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_688869k03ssp4qdft0h043jgv9